Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Advil Label Comprehension Data Counter GI, Renal Warnings’ Merit – Wyeth

This article was originally published in The Tan Sheet

Executive Summary

Almost 98% of participants in a recently conducted Advil label comprehension study understood that individuals who develop stomach pain after taking the OTC ibuprofen tablets should stop use, Wyeth Consumer Care reports

You may also be interested in...



McNeil Supports Separate Alcohol, Stomach Bleeding Warnings For Ibuprofen

McNeil Consumer & Specialty Pharmaceuticals endorses separate warnings for alcohol-related stomach bleeding and general gastrointestinal bleeding for 200 mg ibuprofen because the statements would target separate populations, the firm states in Sept. 2 comments to FDA

McNeil Supports Separate Alcohol, Stomach Bleeding Warnings For Ibuprofen

McNeil Consumer & Specialty Pharmaceuticals endorses separate warnings for alcohol-related stomach bleeding and general gastrointestinal bleeding for 200 mg ibuprofen because the statements would target separate populations, the firm states in Sept. 2 comments to FDA

McNeil Supports Separate Alcohol, Stomach Bleeding Warnings For Ibuprofen

McNeil Consumer & Specialty Pharmaceuticals endorses separate warnings for alcohol-related stomach bleeding and general gastrointestinal bleeding for 200 mg ibuprofen because the statements would target separate populations, the firm states in Sept. 2 comments to FDA

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS094835

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel